[1]杨海光,周启蒙,王海港,等.晶V型芒果苷对高尿酸血症小鼠的作用及其机制研究[J].中国药理学通报,2018,(10):1356-1362.[doi:10.3969/j.issn.1001-1978.2018.10.007]
 YANG Hai-guang,ZHOU Qi-meng,WANG Hai-gang,et al.Effect of mangiferin(crystal Ⅴ)on hyperuricemia mice induced by potassium oxonate and its mechanism[J].Chinese Pharmacological Bulletin,2018,(10):1356-1362.[doi:10.3969/j.issn.1001-1978.2018.10.007]
点击复制

晶V型芒果苷对高尿酸血症小鼠的作用及其机制研究()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2018年10期
页码:
1356-1362
栏目:
论著
出版日期:
2018-10-26

文章信息/Info

Title:
Effect of mangiferin(crystal Ⅴ)on hyperuricemia mice induced by potassium oxonate and its mechanism
文章编号:
1001-1978(2018)10-1356-07
作者:
杨海光1周启蒙1王海港1程 笑1赵晓悦1吕 扬2方莲花1杜冠华1
中国医学科学院北京协和医学院药物研究所 1.北京市药物靶点研究与新药筛选重点实验室、2.北京市晶型药物研究重点实验室,北京 100050
Author(s):
YANG Hai-guang1 ZHOU Qi-meng1 WANG Hai-gang1 CHENG Xiao1 ZHAO Xiao-yue1 LYU Yang2 FANG Lian-hua1 DU Guan-hua1
1.Beijing Key Lab of Drug Targets Identification and Drug Screening, 2.Beijing Key Lab of Polymorphic Drugs, Instiute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
关键词:
晶型 芒果苷 高尿酸血症 尿酸转运体 氧嗪酸钾 黄嘌呤氧化酶
Keywords:
crystalline form mangiferin hyperuricemia oteracil potassium magnesium oxide xanthine oxidase
分类号:
R-332; R284.1; R322.47; R322.61; R446.11; R589.9; R977.3
DOI:
10.3969/j.issn.1001-1978.2018.10.007
文献标志码:
A
摘要:
目的 研究晶V型芒果苷对高尿酸血症小鼠的作用及其机制。方法 70只昆明小鼠随机分成正常对照组、模型组、别嘌呤醇组(25 mg·kg-1)、苯溴马隆组(25 mg·kg-1)、晶V型芒果苷低、中、高剂量组(10、30、100 mg·kg-1)。正常组给予CMC-Na溶液,其余各组连续腹腔注射氧嗪酸钾21 d(300 mg·kg-1),d 8起各组给予相应药物。造模d 21给药后,各组小鼠取血,肝肾称重以计算脏器指数,测定血清生化指标,HE染色观察肾脏病理损伤,检测肾、肠转运体相关mRNA水平、肝黄嘌呤氧化酶活性和mRNA表达水平。结果 晶V型芒果苷组能明显降低高尿酸血症小鼠血尿酸水平,肝肾指数和生化指标无明显改变,适度改善模型小鼠肾脏病理变化。机制研究显示,晶V型芒果苷能抑制黄嘌呤氧化酶的活性和表达,降低肾脏和肠道GLUT9的基因表达,调节PDZK1的表达。结论 晶V型芒果苷可有效降低高尿酸血症小鼠的血尿酸水平,改善肾功能,且对小鼠肝肾无损伤。
Abstract:
Aim To investigate the pharmacological effects of mangiferin(crystal Ⅴ)on the hyperuricemia mice induced by potassium oxonate and its mechanism.Methods Male 70 Kunming mice were randomly divided into normal control group, model group, allopurinol group(25 mg·kg-1), benzbromarone group(25 mg·kg-1), mangiferin(crystal Ⅴ)low(10 mg·kg-1), middle(30 mg·kg-1), and high(100 mg·kg-1)dose groups.The control group received intraperitoneal injection of CMC-Na solution, and the other groups of oteracil potassium(300 mg·kg-1, i.p.)for 21 d.From day 8 to day 21 different groups were treated with different drugs.Blood, liver, kidney were taken and weighted at the end of experiment.Serum biochemical parameters, renal and intestine uric acid transporter mRNA expression, hepatic xanthine oxidase activity and mRNA expression were measured, and renal HE staining was performed.Results Mangiferin(crystal Ⅴ)decreased significantly serum uric acid level, inhibiting the hepatic magnesium oxide(XO)activity.There was no obvious change in liver, kidney index and biochemical index.Further mechanism studies showed that mangiferin(crystal V)inhibited GLUT9 mRNA expression in kidney and intestine, regulated the expression of PDZK1, and improved renal pathological changes.Conclusion Mangiferin(crystal Ⅴ)can remarkably reduce hyperuricbemia and improve the renal function in mice with hyperuricemia, without liver and kidney toxicity.

参考文献/References:

[1] 中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志, 2013,29(11): 913-20.
[1] Chinese Society of Endocrinology.Chinese expert consensus about hyperuricemia and gout treatment[J].Chin J Endocrinol Metab, 2013,29(11):913-20.
[2] Kuo C F, Grainge M J, Zhang W, Doherty M.Global epidemiology of gout: prevalence, incidence and risk factors[J].Nat Rev Rheumatol, 2015, 11(11): 649-62.
[3] 杨海光, 方莲花, 杜冠华.芒果苷的药理作用研究进展[J].中国药理学通报, 2016, 32(1): 5-8.
[3] Yang H G, Fang L H, Du G H.Research progress of pharmacological effect of mangiferin[J].Chin Pharmacol Bull,2016, 32(1): 5-8.
[4] 杜冠华.固体灌胃器:中国,CN201870770U[P].2011-06-22.
[4] Du G H.Fill the stomach: China,CN201870770U[P].2011-06-22.
[5] Rock K L, Kataoka H, Lai J J.Uric acid as a danger signal in gout and its comorbidities[J].Nat Rev Rheumatol, 2013, 9(1):13-23.
[6] Reginato A M, Mount D B, Yang I, Choi H K.The genetics of hyperuricaemia and gout[J].Nat Rev Rheumatol, 2012, 8(10): 610-21.
[7] Hosomi A, Nakanishi T, Fujita T, Tamai I.Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2[J].PLoS One, 2012,7(2): e30456.
[8] Philip K, Tan P K, Liu S, et al.Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout[J].Sci Rep, 2017, 7(1): 665.
[9] Tan P K, Ostertag T M, Miner J N.Mechanism of high affinity inhibition of the human urate transporter URAT1[J].Sci Rep, 2016, 6: 34995.
[10] Shalom R,Rimbroth S,Rozenman D, Markel A.Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment[J].Ren Fail, 2008, 30(3): 327-9.
[11] Assaneeyakul W, Jantararoungtong T, Chen P, et al.Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population[J].Pharmacogenet Genomics, 2009, 19(9): 704-9.
[12] 赵 娟, 张卓莉.高尿酸血症与肾损害[J].中国医学前沿杂志(电子版), 2014, 6(10): 8-10.
[12] Zhao J, Zhang Z L.Hyperuricemia and renal damage[J].Chin J Front Med Sci(Electron Version), 2014, 6(10): 8-10.

相似文献/References:

[1]王阳阳,于惠玲,李田阳,等.HO-1介导芒果苷对大鼠肝脏缺血/再灌注损伤的保护作用[J].中国药理学通报,2015,(05):736.
 WANG Yang-yang,YU Hui-ling,LI Tian-yang,et al.Protective effect of HO-1 mediated mangiferin on liver ischemia/reperfusion injury in rats[J].Chinese Pharmacological Bulletin,2015,(10):736.
[2]运晨霞,杜 军,兰太进,等.芒果苷联合麻黄碱治疗过敏性哮喘的作用研究[J].中国药理学通报,2017,(09):1314.[doi:10.3969/j.issn.1001-1978.2017.09.024]
 YUN Chen-xia,DU Jun,LAN Tai-jin,et al.Mangiferin and ephedrine combined treatment in asthmatic mouse model[J].Chinese Pharmacological Bulletin,2017,(10):1314.[doi:10.3969/j.issn.1001-1978.2017.09.024]

备注/Memo

备注/Memo:
收稿日期:2018-06-15,修回日期:2018-07-24
基金项目:中国医学科学院医学与健康科技创新工程(No 2017-I2M-1-010); 国家重点研发计划专项(No 2016YFC1000900)
作者简介:杨海光(1984-),男,硕士生,研究方向:心脑血管药理学与新药发现,E-mail:yhg@imm.ac.cn;
方莲花(1963-),女,博士,研究员,博士生导师,研究方向:心脑血管药理学与新药发现,通讯作者,Tel:010-63165313,E-mail:fanglh@imm.ac.cn;
杜冠华(1956-),男,博士,研究员,博士生导师,研究方向:神经药理学、心脑血管药理学与新药发现,通讯作者,Tel:010-63165184,E-mail:dugh@imm.ac.cn
更新日期/Last Update: 2018-08-26